News

Although uncommon, blood-clotting problems are more likely to occur in people with Prader-Willi syndrome than in obese individuals without the disorder, researchers report. The study, “Age Distribution, Comorbidities and Risk Factors for Thrombosis in Prader–Willi Syndrome,” was published in the journal Genes. PWS is the most…

Parents of preschoolers with Prader-Willi Syndrome (PWS) tend to be relatively more stressed and overinvolved in interactions with their children, while the children themselves show less interest and social skill in these interactions, compared with their typically developing peers, according to a new study. The study, titled “…

Adenotonsillectomy — a surgery to remove both the adenoids and tonsils — may help ease obstructive sleep apnea (OSA) in children with Prader-Willi syndrome (PWS), a Taiwanese study suggests. However, the procedure’s limited rate of success requires additional therapies post-surgery, the investigators said. The study, “Adenotonsillectomy…

People with Prader-Willi syndrome (PWS) rarely undergo hip or knee replacement surgery, but those who do tend to be younger than their counterparts in the general population, a large U.S. nationwide study reports. The study, “Comparison of Hip and Knee Arthroplasty Rates of Individuals With and Without Prader-Willi…

Non-invasive vagus nerve stimulation (VNS) — which sends signals to a key nerve that runs through the neck — may help reduce temper outbursts and improve quality of life in adults with Prader-Willi syndrome (PWS), a small trial suggests. The study, “Transcutaneous vagus nerve stimulation (t-VNS): A…

A new funding deal will aid Saniona‘s development of Tesomet (tesofensine/metoprolol), a potential therapy to help control appetite and weight in people with Prader-Willi syndrome (PWS) and hypothalamic obesity, the company said. Saniona is planning to conduct a Phase 2b/3 trial, which the Denmark-based company…

Livoletide, a potential therapy to curb excessive eating among people with Prader-Willi syndrome (PWS), is being tested in a global Phase 2b/3 clinical trial called ZEPHYR. Although recruitment of participants ages 8-65 has been completed, enrollment of children ages 4-7 is still ongoing. To date, 4 children…

Target enrollment of approximately 100 participants has been reached in a Phase 3 clinical trial evaluating the investigational oral therapy diazoxide choline controlled-release (DCCR) for reducing excessive appetite in people with Prader-Willi syndrome (PWS), Soleno Therapeutics has announced. Additional patients who are already scheduled to be screened…

The specific type of genetic defects in people with Prader-Willi syndrome (PWS) is associated with distinct physical characteristics such as height, weight, and hair thickness, a study has found. Yet, treatment with growth hormone (GH) therapy seems equally effective regardless of PWS molecular subtype. The findings were…

Medix has submitted a new drug application to the Mexican food and drug administration — Comisión Federal para la Protección contra Riesgos Sanitarios, or COFEPRIS — seeking approval of tesofensine for the treatment of obesity. Tesofensine is one of two compounds that make up Tesomet, which Saniona…